Neurotransmitter Systems (Serotonin, Dopamine, GABA, Glutamate)

Neurotransmitter systems are the chemical signalling networks through which neurons communicate. Four systems are central to psychiatric neurobiology: serotonin and dopamine (modulatory monoamines that shape mood, reward, and motivation) and GABA and glutamate (the brain's principal inhibitory and excitatory transmitters that set the balance of neural activity). Disturbances in these systems are implicated in mood, anxiety, and psychotic disorders, and most psychotropic medications act on them.

Definition

Neurotransmitter systems are organised populations of neurons defined by the chemical messenger they release — here serotonin, dopamine, gamma-aminobutyric acid (GABA), and glutamate — together with the receptors and transporters through which that messenger acts.

Scope

This topic introduces the four neurotransmitter systems most studied in psychiatry, the broad behavioural and cognitive functions associated with each, and how classical chemical hypotheses of mental illness arose from and were later qualified by evidence. It covers concepts at a reference level and does not address dosing or individualised treatment.

Core questions

• What behavioural and cognitive functions are each of these systems associated with?
• How did monoamine hypotheses of depression and psychosis arise, and why are they now seen as incomplete?
• How do excitatory (glutamate) and inhibitory (GABA) signalling maintain the balance of brain activity?

Key concepts

• Serotonin (5-HT)
• Dopamine
• GABA (inhibitory transmitter)
• Glutamate (excitatory transmitter)
• Excitatory-inhibitory balance
• Receptors, transporters, and reuptake
• Monoamine modulation of mood and reward

Key theories

Monoamine hypothesis of depression

The classical proposal that depression results from a deficiency of monoamine neurotransmitters, especially serotonin and noradrenaline, derived from the mood effects of drugs that alter monoamine levels; it remains historically important but is now regarded as an incomplete account of depression's biology.

Dopamine hypothesis of psychosis

The proposal that excess or dysregulated dopaminergic transmission, particularly in mesolimbic pathways, contributes to psychotic symptoms, grounded in the dopamine-blocking action of antipsychotic drugs and refined over time to emphasise regional and circuit specificity.

Mechanisms

Serotonin and dopamine are monoamines released from small brainstem and midbrain nuclei whose axons project widely, modulating mood, reward, motivation, and cognition rather than carrying fast point-to-point signals. GABA and glutamate, by contrast, mediate most fast synaptic transmission: glutamate excites and GABA inhibits, and the balance between them shapes network activity, plasticity, and information processing. Many psychotropic drugs work by altering these systems — for example by blocking monoamine reuptake or transporters, or by acting at glutamate or GABA receptors — which is why chemical hypotheses of psychiatric illness were originally inferred from drug effects. Contemporary accounts stress that monoamine changes are one node within broader circuit and plasticity mechanisms rather than the whole story (Berton & Nestler, 2006).

Clinical relevance

These systems are the targets of most antidepressant, antipsychotic, anxiolytic, and mood-stabilising drugs, so understanding them is central to interpreting how such treatments are thought to work. This entry describes mechanisms for reference and education and is not guidance for prescribing or for any individual treatment decision.

History

Modern interest in neurotransmitter systems in psychiatry dates to the 1950s and 1960s, when observations that reserpine could induce depression and that antipsychotic drugs blocked dopamine led to monoamine and dopamine hypotheses of mood disorder and psychosis. Over subsequent decades these hypotheses were repeatedly qualified as evidence accumulated that neurotransmitter changes alone do not fully explain illness, shifting attention toward downstream signalling, neuroplasticity, and glutamatergic mechanisms.

Debates

Is the monoamine hypothesis sufficient to explain depression?

The delayed therapeutic action of monoamine-targeting antidepressants and the limits of the serotonin-deficiency model have led many researchers to view monoamine changes as part of a broader picture involving plasticity, stress, and glutamatergic signalling rather than the primary cause.

Key figures

• Eric Nestler
• Arvid Carlsson
• Solomon Snyder

Seminal works

• berton-nestler-2006
• nestler-carlezon-2006
• belmaker-agam-2008

Frequently asked questions

What is the difference between GABA and glutamate?

Glutamate is the brain's main excitatory neurotransmitter and GABA its main inhibitory one; the balance between their signalling sets the overall level of neural activity and is important for normal brain function.

Does low serotonin cause depression?

The simple idea that depression is caused by a serotonin deficiency is now considered incomplete; serotonin is one of several interacting systems involved, and current models emphasise broader circuit and plasticity mechanisms.